异动解读 | BioCryst制药盘中大跌业绩疲软或是主因

异动解读11-04

BioCryst制药(BCRX)今日股价盘中大跌16.90%,引发市场广泛关注。公司最新公布的2024年第三季度业绩显示,营收同比增长35%至1.17亿美元,但调整后每股亏损7美分,高于分析师平均预期的6美分亏损,也未达华尔街预期区间。

作为一家专注于开发新型小分子药物治疗感染和炎症疾病的生物技术公司,业绩疲软往往会引发市场对公司长期增长前景的担忧。虽然分析师对该股仍然维持较高评级,但低于预期的财报数据或成为当日股价大跌的主要原因。

不过也有分析人士认为,当前股价剧烈波动可能还与大资金的资金流出有关。根据数据,近期该股大资金净流出达1000万美元,整体资金净流出3000万美元。但具体导致股价重挫的原因,还需进一步观察和分析。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1172966698?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-04 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172966698","market":"us","top_or_hot":-1,"title":"异动解读 | BioCryst制药盘中大跌 业绩疲软或是主因","media":"异动解读","content":"<p>BioCryst制药(BCRX)今日股价盘中大跌16.90%,引发市场广泛关注。公司最新公布的2024年第三季度业绩显示,营收同比增长35%至1.17亿美元,但调整后每股亏损7美分,高于分析师平均预期的6美分亏损,也未达华尔街预期区间。</p>\n\n<p>作为一家专注于开发新型小分子药物治疗感染和炎症疾病的生物技术公司,业绩疲软往往会引发市场对公司长期增长前景的担忧。虽然分析师对该股仍然维持较高评级,但低于预期的财报数据或成为当日股价大跌的主要原因。</p>\n\n<p>不过也有分析人士认为,当前股价剧烈波动可能还与大资金的资金流出有关。根据数据,近期该股大资金净流出达1000万美元,整体资金净流出3000万美元。但具体导致股价重挫的原因,还需进一步观察和分析。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | BioCryst制药盘中大跌 业绩疲软或是主因</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | BioCryst制药盘中大跌 业绩疲软或是主因\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-04 23:30 北京时间&nbsp;&nbsp;&nbsp;<strong>异动解读</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioCryst制药(BCRX)今日股价盘中大跌16.90%,引发市场广泛关注。公司最新公布的2024年第三季度业绩显示,营收同比增长35%至1.17亿美元,但调整后每股亏损7美分,高于分析师平均预期的6美分亏损,也未达华尔街预期区间。\n作为一家专注于开发新型小分子药物治疗感染和炎症疾病的生物技术公司,业绩疲软往往会引发市场对公司长期增长前景的担忧。虽然分析师对该股仍然维持较高评级,但低于预期的...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"","article_id":"1172966698","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172966698","pubTimestamp":1730734232,"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioCryst制药今日股价盘中大跌16.90%,引发市场广泛关注。公司最新公布的2024年第三季度业绩显示,营收同比增长35%至1.17亿美元,但调整后每股亏损7美分,高于分析师平均预期的6美分亏损,也未达华尔街预期区间。作为一家专注于开发新型小分子药物治疗感染和炎症疾病的生物技术公司,业绩疲软往往会引发市场对公司长期增长前景的担忧。不过也有分析人士认为,当前股价剧烈波动可能还与大资金的资金流出有关。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BCRX":"BioCryst制药"},"translate_title":"Interpretation of changes: BioCryst Pharmaceuticals' intraday drop, weak performance may be the main reason","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1},"content_text":"BioCryst制药(BCRX)今日股价盘中大跌16.90%,引发市场广泛关注。公司最新公布的2024年第三季度业绩显示,营收同比增长35%至1.17亿美元,但调整后每股亏损7美分,高于分析师平均预期的6美分亏损,也未达华尔街预期区间。\n作为一家专注于开发新型小分子药物治疗感染和炎症疾病的生物技术公司,业绩疲软往往会引发市场对公司长期增长前景的担忧。虽然分析师对该股仍然维持较高评级,但低于预期的财报数据或成为当日股价大跌的主要原因。\n不过也有分析人士认为,当前股价剧烈波动可能还与大资金的资金流出有关。根据数据,近期该股大资金净流出达1000万美元,整体资金净流出3000万美元。但具体导致股价重挫的原因,还需进一步观察和分析。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172966698"}

异动解读 | BioCryst制药盘中大跌 业绩疲软或是主因

精彩评论

异动解读 | BioCryst制药盘中大跌业绩疲软或是主因